Switching between raltegravir resistance pathways analyzed by deep sequencing
about
Viral quasispecies evolutionDevelopment of elvitegravir resistance and linkage of integrase inhibitor mutations with protease and reverse transcriptase resistance mutationsProlonged and substantial discordance in prevalence of raltegravir-resistant HIV-1 in plasma versus PBMC samples revealed by 454 "deep" sequencingChallenges and opportunities in estimating viral genetic diversity from next-generation sequencing dataPlasmodium falciparum-like parasites infecting wild apes in southern Cameroon do not represent a recurrent source of human malariaSensitive deep-sequencing-based HIV-1 genotyping assay to simultaneously determine susceptibility to protease, reverse transcriptase, integrase, and maturation inhibitors, as well as HIV-1 coreceptor tropism.Targeted deep sequencing of HIV-1 using the IonTorrentPGM platformUse of four next-generation sequencing platforms to determine HIV-1 coreceptor tropism.High-Throughput Sequencing, a VersatileWeapon to Support Genome-Based Diagnosis in Infectious Diseases: Applications to Clinical BacteriologyComparison of illumina and 454 deep sequencing in participants failing raltegravir-based antiretroviral therapy.Applications of next-generation sequencing technologies to diagnostic virology.Raltegravir in HIV-1 infection: Safety and Efficacy in Treatment-naïve Patients.Substitutions at amino acid positions 143, 148, and 155 of HIV-1 integrase define distinct genetic barriers to raltegravir resistance in vivo.Drug Susceptibility and Viral Fitness of HIV-1 with Integrase Strand Transfer Inhibitor Resistance Substitution Q148R or N155H in Combination with Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Resistance Substitutions.Clinical implications of HIV-1 minority variantsImpact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitnessMultiple genetic pathways involving amino acid position 143 of HIV-1 integrase are preferentially associated with specific secondary amino acid substitutions and confer resistance to raltegravir and cross-resistance to elvitegravir.Drug resistance in HIV-1.Combinational therapies for HIV: a focus on EVG/COBI/FTC/TDF.Longitudinal analysis of integrase N155H variants in heavily treated patients failing raltegravir-based regimens.HIV-1 integrase genotyping is reliable and reproducible for routine clinical detection of integrase resistance mutations even in patients with low-level viraemia.Adaptation on a genomic scale.Efficacy and safety of switching to raltegravir plus atazanavir dual therapy in pretreated HIV-1-infected patients over 144 weeks: a cohort study.Impact of the HIV-1 genetic background and HIV-1 population size on the evolution of raltegravir resistance.The Role of HIV-1 Drug-Resistant Minority Variants in Treatment Failure.
P2860
Q27013917-B40B8687-2E42-4EB0-B50D-8869C4B6C8C2Q28481393-003D431E-10C4-431E-A760-3A9DBF7D4D2FQ28484064-C10B8479-21CB-4A4B-8C9D-D5CA9913B51CQ28727944-1CFBCF12-522E-47EB-81CD-81AF7B6C0F38Q31075031-11BE6504-B758-43B4-B98E-8CD5D885EE0BQ33622927-DC726CA5-E39A-48B7-9CAC-91DCA05D7F59Q34451254-D95EE442-1166-455B-82B6-B06146BD3965Q34482589-E32D7CA8-B7D3-44FA-A035-6A69D55ED4E3Q34569184-05BE3B31-E5CD-4DB8-94BC-7395377508FAQ35113300-38CA9CAB-0C6A-46C0-AF03-45557A515D9EQ35600172-33899ECE-D5F2-478E-94F7-79C5243B06D4Q35789343-27C72A8F-B021-42AB-8FC6-EA3ECC786639Q36155580-7C831913-9236-4382-A8D5-CF6C9FAAC151Q36571812-94CB04FB-828B-44DC-9CB4-26EC71754F40Q36811249-4A817B85-1E30-4DEC-A433-99BBB70F8C95Q37026630-A807C1B9-97F6-4E45-B23E-9E8248FF2443Q37124155-E8383AE6-8531-42A5-A64C-3BAE82519ABEQ37967710-DED8D382-01FC-48E8-8A45-06A043CA565AQ38030981-B97BE662-ED11-405D-9260-84C8351907B7Q38400895-A5338733-1323-4289-BB27-AF323294E809Q41465991-FA819BD1-5FB1-4310-BB49-45D3765A732EQ41506206-9934F963-7DC7-4AAA-8DB4-731C9FB0EB58Q41736369-D38542DF-53CD-41DE-B78B-98E2954544B6Q47172282-83995576-6669-4E1B-A359-816D2FE2B112Q47569409-214AEAA5-ACE9-4C3C-A93D-34DCFFECE5B2
P2860
Switching between raltegravir resistance pathways analyzed by deep sequencing
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Switching between raltegravir resistance pathways analyzed by deep sequencing
@ast
Switching between raltegravir resistance pathways analyzed by deep sequencing
@en
type
label
Switching between raltegravir resistance pathways analyzed by deep sequencing
@ast
Switching between raltegravir resistance pathways analyzed by deep sequencing
@en
prefLabel
Switching between raltegravir resistance pathways analyzed by deep sequencing
@ast
Switching between raltegravir resistance pathways analyzed by deep sequencing
@en
P2093
P2860
P1433
P1476
Switching between raltegravir resistance pathways analyzed by deep sequencing
@en
P2093
Frances Male
Kyle Bittinger
Michael D Miller
Richard L Hodinka
Rithun Mukherjee
Shane T Jensen
P2860
P304
P356
10.1097/QAD.0B013E32834B34DE
P407
P577
2011-10-01T00:00:00Z